Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of iloperidone in adolescent patients with
schizophrenia or bipolar I disorder for up to 52 weeks of treatment.